Navigation Links
Antiviral Won't Improve Bell's Palsy Outcome
Date:10/17/2007

Cheap, standard treatment best against the facial paralysis, study finds

WEDNESDAY, Oct. 17 (HealthDay News) -- The antiviral drug acyclovir is no better at easing a form of facial paralysis called Bell's palsy than traditional treatment, a new study finds.

The fact that acyclovir may not be a new, improved treatment option comes as bad news for patients, experts say, but on the other hand, many people afflicted with Bell's palsy do get better with the current regimen.

The study results suggest that these patients may not need to spend money on a second drug that's hardly cheap, noted Dr. Donald Gilden, chairman of the University of Colorado's department of neurology, in Denver.

The study "will likely change practice" by convincing doctors to avoid acyclovir when treating Bell's palsy, said Gilden, who co-authored a commentary accompanying the study findings, published in the Oct. 18 issue of the New England Journal of Medicine.

Bell's palsy strikes up to 40 of every 100,000 people each year, often between ages 30 and 45. An estimated one in 60 people will be affected by the facial paralysis during their lifetime.

Patients typically have trouble moving some parts of their face, which can droop. "It paralyzes the muscles of facial expression affecting the muscles around the eye, so that the eyelids cannot be closed properly, and around the mouth so that smiling, speech and mouth closure are affected," explained study lead author Frank Sullivan, a researcher at the Scottish School of Primary Care in Dundee, Scotland.

The cause is unknown, although there's some suspicion that Bell's palsy may be connected to a viral infection caused by the same strain of herpes that causes cold sores. This infection can recur as shingles long after a chickenpox infection, Sullivan added.

Typically, Bell's palsy clears up on its own over time or after patients are treated with prednisolone, a steroid related to the more commonly known prednisone. Prednisolone stops the immune system from creating so much inflammation.

Still, some patients with Bell's palsy experience permanent facial disfigurement.

In the new study, the Scottish team looked at 496 Bell's palsy patients who were randomly assigned to receive 10 days of one of four treatment regimens: prednisolone; acyclovir; both drugs in combination; or a placebo.

Acyclovir (brand name Zovimax) is widely used to treat genital herpes. According to Gilden, a course of prednisolone costs about $10, compared to $200 for the antiviral drug.

After nine months, 94 percent of those who took prednisolone had recovered, compared to 85 percent of those who took acyclovir. Ninety-three percent of those who took both drugs got better.

Typically, 75 percent to 80 percent of those who take no drugs get better, lead author Sullivan said.

In essence, the study looks at whether patients with Bell's palsy should take antivirals in addition to the steroid, and the answer is that "you probably don't," Gilden said.

More information

Learn more about Bell's palsy from the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: Donald Gilden, M.D., chairman, University of Colorado, Denver; Frank Sullivan, Ph.D., researcher, Scottish School of Primary Care, Dundee, U.K.; Oct. 18, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Roche Commits More Antiviral Pills To Asia For Bird Flu
2. New oral antiviral treatment of cold sores approved
3. Catechins in green tea show antiviral effect on influenza virus
4. Hepatitis B Relapse In Cancer Chemotherapy Can Be Avoided By Antiviral Drug
5. Antiviral Coating On Bank Notes, Photocopiers Could Help Check Epidemics
6. Antiviral Drugs May Be Useful For Easing Shingles Pain
7. Antiviral Drugs Curb Influenza Virus
8. Call For Bird Flu Antiviral Drugs To Be Shared
9. New Ribosome Finding Could Lead to Antiviral Therapies
10. Adding Milk to Black Tea Wont Ruin Its Antioxidant Effects
11. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol ... global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces ... 2017 to June 30, 2017. Iso International LLC recorded unaudited fiscal Q1 profits ...
(Date:7/26/2017)... ... 26, 2017 , ... BioPlus Specialty Pharmacy (BioPlus), ... of the HCV Treatment Path app (version 4.4.0) to keep health care providers ... All of the latest HCV medications are included in this app, including Vosevi™ ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Summers in Palm ... the air conditioner — think homemade gourmet ice cream, sparkling pools, and mile-high fun. ... shop featuring fun mugs, journals, and other must-have knick knacks. Ice cream and sorbet ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance ... services to communities across North Carolina, is launching a charity event in conjunction ... support for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) released ... , M.D., following today,s Institute for Clinical and Economic Review,s ... on the effectiveness and value of abuse-deterrent formulations (ADF) of ... policy roundtable at the meeting. ... material cost benefit to the use of abuse-deterrent formulations (ADF) ...
Breaking Medicine Technology: